Back to News
Apr 30, 2026 8:10 AM

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX Ltd. (NASDAQ:NCEL) reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes program, NCEL-101.

Ronen Twito, executive chairman and CEO, said the company is positioning NCEL-101, developed in partnership with Eledon Pharmaceuticals Inc. (NASDAQ:ELDN), as its primary long-term value driver.

Twito added that the company's stem cell-derived islet platform, combined with targeted immune protection, represents a differentiated approach aimed at a functional cure for Type 1 diabetes.

NCEL-101 Development Gains Momentum

NewcelX advanced its flagship NCEL-101 therapy through IND-enabling activities, including regulatory preparation and preclinical planning.

The company also progressed manufacturing readiness, working with CDMO Pluri Inc. on clinical batch preparations.

The pipeline strategy includes combining stem ...